Through serendipity, researchers at the University of Pittsburgh Graduate School of Public Health considerably reduced the toxicity of a potential antibiotic against the most feared drug-resistant bacteria, while
One of the biggest challenges faced by biomedicine is the development of more selective and efficient cancer treatments. In 2018, 1.7 million people died from lung cancer worldwide,
Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and
On Sept. 16, Tulare County in California announced the nation’s seventh death from vaping-related illness. Its advisory warned about “the dangerous effects of using electronic cigarettes, or e-cigarettes.”
Rare form of pneumonia is among the mysterious vape-related lung illnesses that have sickened 450 across the US, CDC report reveals Five patients were admitted to hospitals in
Patients with non-small cell lung cancer (NSCLC) now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors
Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with
Life-extending pill is APPROVED for patients with aggressive form of lung cancer in dramatic NHS U-turn after drug firm lowered its prices Dacomitinib may help 1,500 people with
Dangerous lung disease: High mortality in COPD More and more people suffer from chronic obstructive pulmonary disease (COPD). However, in many cases, the disease, which is also popularly
Dangerous lung disease: High mortality in COPD More and more people suffer from chronic obstructive pulmonary disease (COPD). However, in many cases, the disease, which is also popularly
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok
